The U.S. Food and Drug Administration’s recent approval of aducanumab, a treatment for Alzheimer’s disease, has drawn decidedly mixed reviews.
By the time people with Alzheimer’s disease start exhibiting difficulty remembering and thinking, the disease has been developing in their brains for two decades or…
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3…
Most of us have heard of Alzheimer’s disease, a neurodegenerative disorder marked by brain cell death and the shrinking of the brain. It is the…
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying…
Identifying the causes of human neurodegenerative diseases is a global research priority, warranting frequent reviews of the accumulating knowledge. In doing just that, biologists from…
Despite near unanimous objection from its advisory panel, the U.S. Food and Drug Administration (FDA) granted aducanumab approval to treat Alzheimer’s disease on June 7,…
Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in…
Research conducted by Qiang et al has discovered a link between a protein in red blood cells and age-related decline in cognitive performance. Published in…
Case Western Reserve University researchers studying prions—misfolded proteins that cause lethal incurable diseases—have identified for the first time surface features of human prions responsible for…